Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma
Brain Tumor, Central Nervous System Tumor
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Childhood Ependymoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Surveillance neuroimaging, coupled with clinical assessments, is generally recommended after treatment for ependymoma. In a report of 198 patients with ependymoma, 90 experienced a relapse. Patients whose relapsed tumor was detected by routine surveillance imaging had superior second PFS than patients whose relapsed tumor was detected by clinical symptomology. The latter were more likely to have metastatic disease at relapse. It is not known whether these patients also had more biologically aggressive disease, although the median time to relapse and the median time from last surveillance imaging was the same in both groups.[42]
Sources: 42
Most practitioners obtain MRI of the brain and/or spinal cord at the following intervals:[43][Level of evidence B4]
Sources: 43 · Level of evidence B4
First 2 to 3 years after treatment: Every 3 to 4 months.
Four to 5 years after treatment: Every 6 months.
More than 5 years after treatment: Annually because of the high incidence of late recurrences.
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Childhood Ependymoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Many of the improvements in survival in patients with childhood cancer have been made as a result of clinical trials that have attempted to improve on the best available, accepted therapy. Clinical trials in pediatrics are designed to compare new therapy with therapy that is currently accepted as standard. This comparison may be done in a randomized study of two treatment arms or by evaluating a single new treatment and comparing the results with those previously obtained with existing therapy.
Because of the relative rarity of cancer in children, all patients with aggressive brain tumors should be considered for entry into a clinical trial. To determine and implement optimum treatment, review of each case by a multidisciplinary team of cancer specialists who have experience treating childhood brain tumors is required. Radiation therapy for pediatric brain tumors is technically demanding and should be performed in centers that have pediatric experience to ensure optimal results.
Treatment of childhood ependymoma begins with surgery. The type of adjuvant therapy given, such as a second surgery, chemotherapy, or radiation therapy, depends on the following:
Subtype of ependymoma.
Location of the tumor.
Whether the tumor was completely removed during the initial surgery.
Whether the tumor has disseminated throughout the central nervous system.
Child's age.
Table 1 describes the standard treatment options for newly diagnosed and recurrent childhood ependymoma.
Sources: Table 1
| Treatment Group | Standard Treatment Options | |
|---|---|---|
| WHO = World Health Organization. | ||
| Newly diagnosed childhood myxopapillary ependymoma (WHO grade 2) | Surgery with or without adjuvant radiation therapy | |
| Newly diagnosed childhood nonmyxopapillary spinal ependymoma | Surgery | |
| Radiation therapy | ||
| Newly diagnosed childhood intracranial (supratentorial or posterior fossa) ependymoma: | Surgery | |
| Adjuvant therapy: | ||
| No residual disease, no disseminated disease | —Radiation therapy | |
| Residual disease, no disseminated disease | —Second-look surgery | |
| —Radiation therapy | ||
| —Preirradiation chemotherapy | ||
| Central nervous system disseminated disease | —Radiation therapy (not considered standard treatment) | |
| —Chemotherapy (not considered standard treatment) | ||
| Children younger than 1 year | —Chemotherapy | |
| —Deferred radiation therapy | ||
| Recurrent childhood ependymoma | Surgery | |
| Radiation therapy and/or chemotherapy | ||
Sources: Surgery with or without adjuvant radiation therapy · Surgery · Radiation therapy · Surgery · Adjuvant therapy · Radiation therapy · Second-look surgery · Radiation therapy · Preirradiation chemotherapy · Radiation therapy · Chemotherapy · Chemotherapy · Deferred radiation therapy · Surgery · Radiation therapy and/or chemotherapy
Dramatic improvements in survival have been achieved for children and adolescents with cancer. Between 1975 and 2020, childhood cancer mortality decreased by more than 50%.[1-3] Childhood and adolescent cancer survivors require close monitoring because cancer therapy side effects may persist or develop months or years after treatment. For specific information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors, see Late Effects of Treatment for Childhood Cancer.
Sources: 1 · 3 · Late Effects of Treatment for Childhood Cancer
Source: Childhood Ependymoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Myxopapillary ependymoma, considered to be a histological subtype of ependymoma, has a relatively high incidence of central nervous system (CNS) tumor dissemination at diagnosis and at follow-up. Imaging of the complete craniospinal axis at the time of diagnosis and during follow-up is indicated.[1,2] According to the 2021 World Health Organization (WHO) Classification of Tumors of the CNS, myxopapillary ependymoma is now considered WHO grade 2 rather than grade 1 because its recurrence rate is similar to conventional spinal ependymoma and exceeds the rate typical of grade 1 tumors.[3]
Standard treatment options for newly diagnosed childhood myxopapillary ependymoma include the following:
Surgery with or without adjuvant radiation therapy.
Historically, the management of myxopapillary ependymoma consisted of an attempt at en bloc resection of the tumor with no further treatment in the case of a gross-total resection.[4]; [5][Level of evidence C2] However, some practitioners now favor the use of radiation therapy after surgical resection of the primary mass. This practice is based on the finding that dissemination of these tumors to other parts of the neuraxis can occur, particularly after partial resection, and evidence that focal radiation therapy may improve progression-free survival (PFS).[1,4]; [6-8][Level of evidence C2]
Sources: 4 · 5 · Level of evidence C2 · 1 · 4 · 6 · 8 · Level of evidence C2
With the exception of an en bloc gross-total resection where the utility of adjuvant radiation therapy has been debated, radiation therapy is often considered for patients with less than a gross-total resection, a piecemeal resection, or locally recurrent disease after surgery alone. A retrospective single-institution review included 18 pediatric patients with myxopapillary ependymoma.[9]
Sources: 9
The study reported poor 5-year and 10-year event-free survival (EFS) rates of 52% and 26%, respectively.
However, these patients had an excellent 10-year overall survival (OS) rate of 100%.
Fifty percent of the patients had metastatic disease at diagnosis and 50% had subtotal resections, but only three patients received radiation therapy (two received focal and one received craniospinal).
The extent of resection did not affect the EFS rate.
Metastatic disease was associated with a worse EFS (10-year EFS rate, 13%), compared with localized disease (57%; P = .07).
This study concluded that despite the high risk of recurrence, patients with myxopapillary ependymoma have an excellent long-term survival. Therefore, radiation therapy should be reserved for patients with symptomatic recurrences to avoid long-term complications from radiation exposure.
However, two reports provided some support for the use of radiation therapy for patients with multifocal spinal myxopapillary ependymoma. The first study included 12 children (aged <21 years) who were treated with limited-volume brain-sparing proton radiation therapy. The median age of patients was 13.5 years. Radiation therapy was given as adjuvant therapy after primary surgery in five patients and for recurrence in seven patients. No patient had previously received radiation therapy. Of the 12 patients, 11 (92%) had evidence of gross disease at the time of radiation therapy, and all but one patient received 54 Gy relative biological effectiveness (RBE) of radiation therapy.[10]
Sources: 10
With a median follow-up of 3.6 years (range, 1.8–10.6 years), the 5-year local control rate was 100%, the PFS rate was 92%, and the OS rate was 100%.
One patient developed grade 3 spinal kyphosis after combined surgery and radiation therapy, and one patient developed grade 2 unilateral L5 neuropathy.
A second multi-institutional retrospective study of 60 pediatric and adolescent and young adult (AYA) patients also suggested a benefit of radiation therapy (2000–2020). The median age at radiation therapy was 14.8 years (range, 7.1–26.5 years). The population was high risk because the indications for radiation therapy included gross residual disease, microscopic residual disease, or recurrent or multifocal disease.[11]
Sources: 11
At the time of radiation therapy, 45 patients (75.0%) had gross residual disease, and 35 patients (58.3%) had multifocal disease.
Forty-eight patients (80.0%) received involved-field radiation therapy (IFRT), seven (11.7%) received cranial-spinal radiation therapy, and five (8.3%) received whole-spine radiation therapy.
With a median follow-up of 6.2 years (range, 0.6–21.0 years), the 5-year OS rate was 100%, the PFS rate was 60.8%, and the cumulative incidence of local in-field progression rate was 4.1%.
The two local recurrences were in sites of gross residual disease. Of the 18 out-of-field recurrences after radiation therapy, all were superior to the initial treatment field. Nine of these patients experienced intracranial relapse (five of whom had isolated intracranial relapses).
For patients with metastatic myxopapillary ependymoma, there was no significant difference in PFS between patients treated with IFRT (to all sites) and those treated with whole-brain or craniospinal irradiation (P = .283).
On univariate analysis, distant-only recurrence before radiation therapy was significantly associated with shorter time to progression (HR, 4.00; 95% CI, 1.54–10.43; P = .005).
Conclusions from this report include: 1) the risk of recurrence within the radiation field is low, and 2) pediatric and AYA patients with high-risk myxopapillary ependymoma remain at risk for recurrences in the spine above the radiation fields and intracranially after radiation therapy.
Source: Childhood Ependymoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Standard treatment options for newly diagnosed childhood nonmyxopapillary spinal ependymoma include the following:
Surgery.
Radiation therapy.
Although studies suggest that surgery alone may be adequate for many grade 1 tumors, adjuvant radiation therapy may improve survival in patients with nonmyxopapillary high-grade (2/3) tumors. A bicentric report from the University of Florida and Massachusetts General Hospital supports the use of radiation therapy for tumor control.[1-3]
Between 2008 and 2019, 14 pediatric patients with nonmetastatic nonmyxopapillary grade 2 (n = 6) and grade 3 (n = 8) spinal ependymomas were treated with radiation therapy doses between 50.4 Gy relative biological effectiveness (RBE) and 54 Gy RBE (protons). The median age for patients at the time of radiation therapy was 14 years (range, 1.5–18 years). Before radiation therapy, 3 patients underwent subtotal resection, and 11 patients had gross-total or near-total resections.[4]
Sources: 4
With a median follow-up of 6.3 years (range, 1.5–14.8 years), no tumors progressed.
Although most patients experienced neurological sequelae after surgery, only one developed additional neurological deficits after radiation therapy.
Source: Childhood Ependymoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Standard treatment options for newly diagnosed childhood intracranial ependymoma include the following:
Surgery.
Sources: Surgery
Adjuvant therapy.
Sources: Adjuvant therapy
Adjuvant therapy.
Treatment of no residual disease, no disseminated disease.
Sources: Treatment of no residual disease, no disseminated disease
Treatment of residual disease, no disseminated disease.
Sources: Treatment of residual disease, no disseminated disease
Treatment of central nervous system (CNS) disseminated disease.
Sources: Treatment of central nervous system (CNS) disseminated disease
Treatment of children younger than 1 year.
Typically, all patients undergo surgery to remove the tumor. Whether additional treatment is given depends on the ependymoma subtype, age of the child, extent of tumor resection, and whether disseminated disease is present.
Source: Childhood Ependymoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Surgery is performed in an attempt at maximal tumor reduction. Evidence suggests that more extensive surgical resection is related to an improved rate of survival.[1-5]; [6,7][Level of evidence C2] Magnetic resonance imaging (MRI) is performed postoperatively to confirm the extent of resection. If not obtained preoperatively, MRI of the entire neuraxis and cerebrospinal fluid cytopathology is performed to evaluate for disease dissemination.
Sources: 1 · 5 · 6 · 7 · Level of evidence C2
Patients across all molecular subgroups who have residual tumor or disseminated disease are considered at high risk of relapse and may be treated on clinical trials specifically designed for them. Patients with no evidence of residual tumor still have an approximate 20% to 40% relapse risk despite receiving postoperative radiation therapy.[8][Level of evidence B4]
Sources: 8 · Level of evidence B4
Anecdotal experience suggests that surgery alone for completely resected supratentorial World Health Organization (WHO) grade 2 tumors and spinal ependymomas may, in select cases, be an appropriate approach to treatment.[9-13][Level of evidence C2]
Sources: 9 · 13 · Level of evidence C2
Evidence (surgery):
A prospective multi-institutional cooperative group trial (Children's Oncology Group [COG] ACNS0121 [NCT00027846]) included patients with newly diagnosed intracranial ependymomas (N = 356). Surgery alone was used for the treatment of supratentorial, WHO grade 2, gross-totally resected ependymomas (n = 11).[8][Level of evidence B4]
Sources: ACNS0121 [NCT00027846] · 8 · Level of evidence B4
A prospective multi-institutional cooperative group trial (Children's Oncology Group [COG] ACNS0121 [NCT00027846]) included patients with newly diagnosed intracranial ependymomas (N = 356). Surgery alone was used for the treatment of supratentorial, WHO grade 2, gross-totally resected ependymomas (n = 11).[8][Level of evidence B4]
The 5-year event-free survival (EFS) rate was 61.4%, and the overall survival (OS) rate was 100%.
Local failure occurred in four patients (36%), and local and distant failure occurred in one patient (9%).
In this study, the number of patients eligible for a surgery-alone approach was very small. Only a subset of these patients successfully avoided additional treatment.
Retrospective analysis of the outcome for patients with posterior fossa B ependymoma suggests that these patients might be sufficiently treated with gross-total resection alone,[7] but this approach has not been tested in a prospective randomized clinical trial.
Sources: 7
Source: Childhood Ependymoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Source: Childhood Ependymoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Source: Childhood Ependymoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
The standard postsurgical treatment for these patients has been radiation therapy consisting of 54 Gy to 59.4 Gy to the tumor bed for children aged 3 years and older.[5,14] The ACNS0121 (NCT00027846) study extended the use of radiation therapy (54 Gy) to patients as young as 1 year, resulting in similar EFS and OS rates when compared with children older than 3 years.[8][Level of evidence B4]
Sources: 5 · 14 · ACNS0121 (NCT00027846) · 8 · Level of evidence B4
It is not necessary to treat the entire CNS (whole brain and spine) because these tumors usually recur initially at the local site, although posterior fossa ependymomas may disseminate at recurrence, particularly in tumors with 1q gain.[15]; [16][Level of evidence C1]
Sources: 15 · 16 · Level of evidence C1
Evidence (radiation therapy):
In one single-institution study, 74 patients aged 1 to 21 years were treated with conformal radiation therapy immediately after surgery.[17]
Sources: 17
In one single-institution study, 74 patients aged 1 to 21 years were treated with conformal radiation therapy immediately after surgery.[17]
The 3-year progression-free survival (PFS) rate was 77.6% (± 5.8%).
In an expansion of the above series, 107 of 153 patients received conformal radiation therapy immediately after up-front resection.[5][Level of evidence C1]
Sources: 5 · Level of evidence C1
In an expansion of the above series, 107 of 153 patients received conformal radiation therapy immediately after up-front resection.[5][Level of evidence C1]
The 7-year EFS rate was 76.9% (± 13.5%).
A COG prospective study (ACNS0121 [NCT00027846]) enrolled 356 patients between the ages of 1 and 21 years with newly diagnosed ependymoma into four strata.[8][Level of evidence B4]
Sources: ACNS0121 [NCT00027846] · 8 · Level of evidence B4
A COG prospective study (ACNS0121 [NCT00027846]) enrolled 356 patients between the ages of 1 and 21 years with newly diagnosed ependymoma into four strata.[8][Level of evidence B4]
Stratum 1: Patients with completely resected differentiated histology supratentorial ependymomas who were treated without radiation therapy.
A COG prospective study (ACNS0121 [NCT00027846]) enrolled 356 patients between the ages of 1 and 21 years with newly diagnosed ependymoma into four strata.[8][Level of evidence B4] › Stratum 1: Patients with completely resected differentiated histology supratentorial ependymomas who were treated without radiation therapy.
The 5-year PFS rate was 61.4% (95% confidence interval, 34.5%–89.6%), with no deaths at 7 years, although only 11 patients were enrolled in this stratum.
A COG prospective study (ACNS0121 [NCT00027846]) enrolled 356 patients between the ages of 1 and 21 years with newly diagnosed ependymoma into four strata.[8][Level of evidence B4]
Stratum 2: Patients with subtotally resected ependymomas (both supratentorial and infratentorial) with more than 5 mm residual disease. Treatment consisted of two cycles of chemotherapy followed by second-look surgery and conformal radiation therapy to the tumor bed (adding a 1-cm target clinical volume). Radiation doses were 54 Gy for patients aged 12 to 18 months and 59.4 Gy for patients older than 18 months.
A COG prospective study (ACNS0121 [NCT00027846]) enrolled 356 patients between the ages of 1 and 21 years with newly diagnosed ependymoma into four strata.[8][Level of evidence B4] › Stratum 2: Patients with subtotally resected ependymomas (both supratentorial and infratentorial) with more than 5 mm residual disease. Treatment consisted of two cycles of chemotherapy followed by second-look surgery and conformal radiation therapy to the tumor bed (adding a 1-cm target clinical volume). Radiation doses were 54 Gy for patients aged 12 to 18 months and 59.4 Gy for patients older than 18 months.
The 5-year PFS rate was 25% for patients in whom a second surgery was not feasible, and 50% for patients in whom a second surgery resulted in a gross-total resection.
A COG prospective study (ACNS0121 [NCT00027846]) enrolled 356 patients between the ages of 1 and 21 years with newly diagnosed ependymoma into four strata.[8][Level of evidence B4]
Stratum 3 and stratum 4: Patients with near-total resection (stratum 3) and gross-total resection (stratum 4). Patients aged 12 to 18 months received postoperative radiation therapy doses of 54 Gy, and patients older than 18 months received doses of 59.4 Gy (adding a 1-cm target clinical volume).
A COG prospective study (ACNS0121 [NCT00027846]) enrolled 356 patients between the ages of 1 and 21 years with newly diagnosed ependymoma into four strata.[8][Level of evidence B4] › Stratum 3 and stratum 4: Patients with near-total resection (stratum 3) and gross-total resection (stratum 4). Patients aged 12 to 18 months received postoperative radiation therapy doses of 54 Gy, and patients older than 18 months received doses of 59.4 Gy (adding a 1-cm target clinical volume).
The 5-year PFS rate was 68.5% (range, 62.8%–74.2%).
Posterior fossa A ependymoma (PF-EPN-A), 1q balanced (without 1q gain): The 5-year PFS rate was 81.5% (range, 71.5%–91.5%).
PF-EPN-A, 1q gain: The 5-year PFS rate was 35.7% (range, 12.8%–58.6%).
For patients with PF-EPN-A, distant failure was more common in patients with 1q gain than in patients with 1q balanced (without 1q gain).
Supratentorial ependymomas: 30 of 39 patients with supratentorial ependymomas who were tested harbored ZFTA fusions, 23 of whom were in stratums 3 and 4. There was no significant difference in survival. The 5-year OS rates exceeded 80%.
Proton-beam radiation therapy (a type of charged-particle radiation therapy) provides a possible advantage for targeting the tumor (supratentorial or infratentorial) while avoiding critical normal brain and neuroendocrine tissues.Concerns about brain stem toxicity in very young children (aged <3 years) after proton therapy to the posterior fossa have prompted the use of more conservative doses in these children at some centers.[21-23]
Sources: charged-particle radiation therapy · 21 · 23
Proton-beam radiation therapy (a type of charged-particle radiation therapy) provides a possible advantage for targeting the tumor (supratentorial or infratentorial) while avoiding critical normal brain and neuroendocrine tissues.Concerns about brain stem toxicity in very young children (aged <3 years) after proton therapy to the posterior fossa have prompted the use of more conservative doses in these children at some centers.[21-23]
In a report from the Massachusetts General Hospital, 150 patients (aged <22 years) with WHO grade 2 and grade 3 ependymomas were treated with proton radiation therapy between 2001 and 2019. The median follow-up was 6.5 years.[18]
Sources: 18
Proton-beam radiation therapy (a type of charged-particle radiation therapy) provides a possible advantage for targeting the tumor (supratentorial or infratentorial) while avoiding critical normal brain and neuroendocrine tissues.Concerns about brain stem toxicity in very young children (aged <3 years) after proton therapy to the posterior fossa have prompted the use of more conservative doses in these children at some centers.[21-23] › In a report from the Massachusetts General Hospital, 150 patients (aged <22 years) with WHO grade 2 and grade 3 ependymomas were treated with proton radiation therapy between 2001 and 2019. The median follow-up was 6.5 years.[18]
For the intracranial cohort (n = 145), the 7-year EFS rate was 63.4%, the OS rate was 82.6%, and the local control rate was 76.1%.
Fifty-one patients experienced a tumor recurrence: 26 patients (51%) had local failures, 19 patients (37.3%) had distant failures, and 6 patients (11.8%) had synchronous failures.
Of the 150 patients, 116 (77.3%) underwent gross-total resection, 5 (3.3%) underwent near-total resection, and 29 (19.3%) underwent subtotal resection.
For the intracranial cohort, the 7-year EFS rate was 70.3% for patients who underwent a gross-total resection or near-total resection and 35.2% for patients who underwent a subtotal resection.
With multivariate analysis, the effect of tumor excision persisted after controlling for tumor location.
Proton-beam radiation therapy (a type of charged-particle radiation therapy) provides a possible advantage for targeting the tumor (supratentorial or infratentorial) while avoiding critical normal brain and neuroendocrine tissues.Concerns about brain stem toxicity in very young children (aged <3 years) after proton therapy to the posterior fossa have prompted the use of more conservative doses in these children at some centers.[21-23]
In a combined Massachusetts General Hospital and University of Florida study, 386 children with nonmetastatic intracranial grade 2 and grade 3 ependymomas were treated with proton radiation therapy.[19]
Sources: 19
Proton-beam radiation therapy (a type of charged-particle radiation therapy) provides a possible advantage for targeting the tumor (supratentorial or infratentorial) while avoiding critical normal brain and neuroendocrine tissues.Concerns about brain stem toxicity in very young children (aged <3 years) after proton therapy to the posterior fossa have prompted the use of more conservative doses in these children at some centers.[21-23] › In a combined Massachusetts General Hospital and University of Florida study, 386 children with nonmetastatic intracranial grade 2 and grade 3 ependymomas were treated with proton radiation therapy.[19]
With a median follow-up of 5 years, the 7-year local control rate was 77%, the PFS rate was 63.8%, and the OS rate was 82%.
As with the previous report, subtotal resection was associated with worse local control, PFS, and OS.
Radiation therapy doses of greater than 54 Gy were not associated with improved disease control or survival.
The rate of brain stem toxicity greater than grade 2 was 4%, and two children died of brain stem toxicity.
Proton-beam radiation therapy (a type of charged-particle radiation therapy) provides a possible advantage for targeting the tumor (supratentorial or infratentorial) while avoiding critical normal brain and neuroendocrine tissues.Concerns about brain stem toxicity in very young children (aged <3 years) after proton therapy to the posterior fossa have prompted the use of more conservative doses in these children at some centers.[21-23]
In the KiProReg study, 105 children with intracranial ependymomas were treated with a median total dose of 59.4 Gy of proton radiation therapy. Children younger than 4 years received 54 Gy. The median follow-up was 1.9 years.[20]
Sources: 20
Proton-beam radiation therapy (a type of charged-particle radiation therapy) provides a possible advantage for targeting the tumor (supratentorial or infratentorial) while avoiding critical normal brain and neuroendocrine tissues.Concerns about brain stem toxicity in very young children (aged <3 years) after proton therapy to the posterior fossa have prompted the use of more conservative doses in these children at some centers.[21-23] › In the KiProReg study, 105 children with intracranial ependymomas were treated with a median total dose of 59.4 Gy of proton radiation therapy. Children younger than 4 years received 54 Gy. The median follow-up was 1.9 years.[20]
The estimated 3-year OS rate was 93.7%, the local control rate was 74.1%, and the PFS rate was 55.6%.
Multiple surgeries were identified as a risk factor for lower PFS.
There was a low rate of grade 3 toxicities and there were no episodes of symptomatic brain stem necrosis.
The International Society of Paediatric Oncology (SIOP) Ependymoma I study included 74 eligible pediatric patients with localized ependymomas. Thirty-three patients underwent a gross-total resection before receiving focal irradiation.[24][Level of evidence B4]
Sources: 24 · Level of evidence B4
The International Society of Paediatric Oncology (SIOP) Ependymoma I study included 74 eligible pediatric patients with localized ependymomas. Thirty-three patients underwent a gross-total resection before receiving focal irradiation.[24][Level of evidence B4]
The 5-year EFS rate was 69%, and the 10-year EFS rate was 63%.
The 5-year OS rate was 81%, and the 10-year OS rate was 68%.
Post hoc analysis of known risk factors confirmed the impact of 1q gain, H3K27me3 loss, and hTERT expression.
When possible, pediatric patients should be treated in a center experienced with the delivery of highly conformal radiation therapy (including intensity-modulated radiation therapy or charged-particle radiation therapy [e.g., proton radiation therapy]) to minimize long-term side effects.
Sources: conformal radiation therapy · intensity-modulated radiation therapy · charged-particle radiation therapy
Source: Childhood Ependymoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Current treatment approaches do not include chemotherapy as a standard component of primary therapy for children with newly diagnosed ependymomas that are completely resected. The utility of adjuvant chemotherapy was studied in the completed COG ACNS0831 (NCT01096368) trial. Published results of this trial are forthcoming. There is no evidence that myeloablative chemotherapy [25] improves the outcome for patients with totally resected, nondisseminated ependymomas.
Sources: ACNS0831 (NCT01096368) · 25
Source: Childhood Ependymoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Source: Childhood Ependymoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Second-look surgery should be considered because patients who have complete resections followed by irradiation have better disease control.[26] In some cases, further surgery can be undertaken after the initial attempted resection if the pediatric neurosurgeon believes that a gross-total resection could be obtained by an alternate surgical approach to the tumor. In other cases, additional up-front surgery is not anticipated to result in a gross-total resection; therefore, adjuvant therapy is initiated with future consideration of second-look surgery.[8]
Source: Childhood Ependymoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
The rationale for radiation therapy, as described in the Treatment of no residual disease, no disseminated disease section above, also pertains to the treatment of children with residual nondisseminated ependymoma. In patients who had a subtotal resection, treatment with radiation therapy results in a 5-year PFS rate of 25%. Outcome is particularly poor for patients with PF-EPN-A,[8] although the outcome may be better for patients with residual tumor within the spinal canal.[27]
Sources: Treatment of no residual disease, no disseminated disease · 8 · 27
Source: Childhood Ependymoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
The rationale for using chemotherapy in patients with residual tumor is to attempt to achieve a state of no evidence of disease before the patients undergo radiation therapy, either by achieving a complete response (CR) to chemotherapy alone or by facilitating the likelihood of a gross-total resection at the time of second-look surgery after chemotherapy. The benefit of chemotherapy for residual tumor after up-front surgery is still being investigated.
Evidence (preirradiation chemotherapy with or without surgery):
One study demonstrated a benefit of preirradiation chemotherapy in children with near-total resection (>90% resection), with outcomes similar to those for children achieving a gross-total resection followed by radiation therapy.[28]
Sources: 28
The COG ACNS0121 (NCT00027846) trial included two cycles of preirradiation chemotherapy for children with residual disease after up-front surgery (n = 64).[8][Level of evidence B4]
Sources: ACNS0121 (NCT00027846) · 8 · Level of evidence B4
The COG ACNS0121 (NCT00027846) trial included two cycles of preirradiation chemotherapy for children with residual disease after up-front surgery (n = 64).[8][Level of evidence B4]
Second-look surgery occurred in 39% of patients (n = 25) (gross-total resection, 56%; near-total resection, 20%; subtotal resection, 24%).
For patients who underwent second-look surgery, the 5-year EFS rate was 50.5%, compared with 28.5% for patients who did not undergo second surgery (P = .12).
A multi-institutional trial for children younger than 3 years used preirradiation chemotherapy, followed by conformal radiation once the child was older than 12 months, followed by maintenance chemotherapy.[29][Level of evidence B4]
Sources: 29 · Level of evidence B4
A multi-institutional trial for children younger than 3 years used preirradiation chemotherapy, followed by conformal radiation once the child was older than 12 months, followed by maintenance chemotherapy.[29][Level of evidence B4]
Fifty-four patients were enrolled, and 54% of patients (n = 29) underwent a gross-total resection at diagnosis.
Of the remaining 25 patients, 60% (n = 15) underwent a second-look surgery after chemotherapy, with 80% of patients achieving a gross-total resection.
At the time of radiation therapy, 76% of patients had a gross-total resection, 13% of patients had a near-total resection, and 11% of patients had a subtotal resection.
PFS (but not OS) was better for patients who underwent a gross-total resection or near-total resection before radiation therapy than it was for patients who underwent a subtotal resection (4-year PFS rate, 79% for gross-total resection/near-total resection vs. 41.7% for subtotal resection) (P = .024).
The SIOP Ependymoma I study enrolled 74 patients, 41 of whom had a subtotal resection after initial surgical management. The protocol specified that these patients were to receive up to four cycles of preirradiation vincristine, etoposide, and cyclophosphamide (VEC). Of the 41 patients, 10 did not receive the protocol-specified VEC therapy, and 3 patients opted for no further therapy and did not receive radiation therapy.[24][Level of evidence B4]
Sources: 24 · Level of evidence B4
The SIOP Ependymoma I study enrolled 74 patients, 41 of whom had a subtotal resection after initial surgical management. The protocol specified that these patients were to receive up to four cycles of preirradiation vincristine, etoposide, and cyclophosphamide (VEC). Of the 41 patients, 10 did not receive the protocol-specified VEC therapy, and 3 patients opted for no further therapy and did not receive radiation therapy.[24][Level of evidence B4]
Of the 29 patients who received VEC, the combined complete response and partial response rate was 65%, which exceeded the prespecified 45% response rate threshold.
Eight of 29 patients had progressive disease at the completion of VEC chemotherapy. The 5-year and 10-year EFS rates were 34%. The 5-year OS rate was 60%, and the 10-year OS rate was 54%.
The study demonstrated chemoresponsiveness in most patients. However, the small number of patients precluded a determination of the added benefit of preirradiation VEC in either facilitating a subsequent gross-total resection or in a survival benefit, compared with patients with a subtotal resection who opted not to receive VEC before radiation therapy.
There is no evidence that high-dose chemotherapy with stem cell rescue is beneficial.[30]; [31][Level of evidence B4]
Sources: 30 · 31 · Level of evidence B4
Source: Childhood Ependymoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Source: Childhood Ependymoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Regardless of the degree of surgical resection, patients with CNS disseminated disease generally receive radiation therapy to the whole brain and spine, along with boosts to local disease and bulk areas of disseminated disease. The traditional local postsurgical radiation doses in these patients are 54 Gy to 55.8 Gy. Doses of approximately 36 Gy to the entire neuraxis (i.e., the whole brain and spine) are also administered but may be modulated depending on the age of the patient.[32] Boosts between 41.4 Gy and 50.4 Gy to bulk areas of spinal disease are administered, with doses depending on the age of the patient and the location of the tumor. However, there are no contemporary studies published to support this approach.
Sources: 32
Source: Childhood Ependymoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
While chemotherapy is often used because of some degree of chemoresponsiveness, evidence demonstrating improvement in EFS and OS is lacking.[33]
Sources: 33
Source: Childhood Ependymoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Source: Childhood Ependymoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Some, but not all, chemotherapy regimens induce objective responses in children younger than 3 years with newly diagnosed ependymomas.[34-37] The goal of chemotherapy is to avoid radiation, defer radiation until the child is older, or achieve a state of no evidence of disease before undergoing radiation therapy (either by a CR to chemotherapy or by a gross-total resection at time of second-look surgery after chemotherapy). Up to 25% of infants and young children with totally resected disease may achieve long-term survival. These studies have not been molecularly characterized, and it is unclear which patients may benefit from chemotherapy-only regimens. Survivors of chemotherapy-only protocols may eventually receive salvage radiation therapy.[38]; [39][Level of evidence B4]
Sources: 34 · 37 · 38 · 39 · Level of evidence B4
Source: Childhood Ependymoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Historically, postoperative radiation therapy was omitted for children younger than 3 years with ependymomas. Two COG studies (POG-9233 and ACNS0121 [NCT00027846]) and many subsequent trials have lowered the age limit for postoperative radiation therapy to 1 year in an effort to improve outcomes for these younger children. The ACNS0121 trial showed that conformal radiation in children with completely resected tumors resulted in significantly improved outcomes compared with patients who received chemotherapy alone.[8][Level of evidence B4]
Sources: ACNS0121 [NCT00027846] · 8 · Level of evidence B4
It is unclear which patients can benefit from radiation-sparing approaches. However, comparison of the POG-9233 trial results with the ACNS0121 (NCT00027846) trial results suggests a 50% to 60% improvement in survival for patients who were treated with radiation therapy.[8,38] A prospective evaluation of molecular markers may identify the infants who can be safely treated with radiation-sparing approaches and/or patients who may benefit from chemotherapy.
Sources: ACNS0121 (NCT00027846) · 8 · 38
Evidence (radiation therapy):
Retrospective reviews based on Surveillance, Epidemiology, and End Results Program data from children younger than 3 years at diagnosis were accrued over a 50-year period.[40]
Sources: 40
Retrospective reviews based on Surveillance, Epidemiology, and End Results Program data from children younger than 3 years at diagnosis were accrued over a 50-year period.[40]
Results showed that patients who received local radiation therapy had better 10-year survival rates, even after adjusting for the extent of resection and tumor grade (WHO grade 2 vs. grade 3).
A large retrospective study, across 820 molecularly characterized posterior fossa ependymomas, demonstrated the following:[7]
Sources: 7
A large retrospective study, across 820 molecularly characterized posterior fossa ependymomas, demonstrated the following:[7]
Adjuvant first-line radiation therapy, along with complete resection and PF-EPN-B subgroup, were associated with an improved prognosis.
Radiation-sparing approaches were associated with dismal outcomes in children with PF-EPN-A tumors.
Conformal or charged-particle (e.g., proton) radiation therapy is an alternative approach for minimizing radiation-induced neurological damage in young children with ependymomas. The need and timing of radiation therapy for children who have successfully completed chemotherapy and have no residual disease is still to be determined.
Conformal or charged-particle (e.g., proton) radiation therapy is an alternative approach for minimizing radiation-induced neurological damage in young children with ependymomas. The need and timing of radiation therapy for children who have successfully completed chemotherapy and have no residual disease is still to be determined.
The initial experience with this approach suggested that children younger than 3 years with ependymomas have neurological deficits at diagnosis that improve with time after conformal radiation treatment.[17]
Sources: 17
Another study suggested that there was a trend for intellectual deterioration over time, even in older children treated with localized radiation therapy.[41]; [42][Level of evidence C1]
Sources: 41 · 42 · Level of evidence C1
The COG ACNS0121 (NCT00027846) study showed that children aged 1 year to younger than 3 years who underwent a gross-total resection or near-total resection followed by immediate postoperative radiation therapy had the following results:[8][Level of evidence B4]
Sources: ACNS0121 (NCT00027846) · 8 · Level of evidence B4
The COG ACNS0121 (NCT00027846) study showed that children aged 1 year to younger than 3 years who underwent a gross-total resection or near-total resection followed by immediate postoperative radiation therapy had the following results:[8][Level of evidence B4]
The 5-year EFS rate was 62.9%, and the OS rate was 87.4%.
These results were not statistically different from the results seen in patients aged 3 to 21 years, who had a 5-year EFS rate of 70.5% and an OS rate of 85.8%.
A multi-institutional trial of children younger than 3 years with newly diagnosed ependymomas (n = 54) who received four to six cycles of chemotherapy followed by radiation therapy (once they had reached the age of 12 months) resulted in the following:[29][Level of evidence B4]
Sources: 29 · Level of evidence B4
A multi-institutional trial of children younger than 3 years with newly diagnosed ependymomas (n = 54) who received four to six cycles of chemotherapy followed by radiation therapy (once they had reached the age of 12 months) resulted in the following:[29][Level of evidence B4]
The 4-year PFS rate was 75.1%, and the OS rate was 92.6%.
These results were comparable to the results seen in studies that treated children older than 3 years.
Of interest, there was no difference in outcomes between infants younger than 1 year and children aged 1 to 3 years at diagnosis.
Conformal radiation approaches, including 3-dimensional conformal radiation therapy that minimizes damage to normal brain tissue and charged-particle radiation therapy, such as proton-beam therapy, are under evaluation for infants and children with ependymomas.[17,43] When analyzing neurological outcomes after treatment of young children with ependymomas, it is important to consider that not all long-term deficits can be attributed to radiation therapy, because deficits may be present in young children before therapy begins.[17] For example, the presence of hydrocephalus at diagnosis is associated with a lower intelligence quotient, as measured after surgical resection and before administration of radiation therapy.[44]
Sources: 3-dimensional conformal radiation therapy · charged-particle radiation therapy · 17 · 43 · 17 · 44
Source: Childhood Ependymoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Early-phase therapeutic trials may be available for selected patients. These trials may be available via the COG, the Pediatric Brain Tumor Consortium, or other entities. Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Sources: COG · Pediatric Brain Tumor Consortium · NCI website · ClinicalTrials.gov website
Source: Childhood Ependymoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Recurrence is not uncommon for all grades of ependymoma and may develop many years after initial treatment.[1,2] Late recurrence beyond 10 to 15 years has been reported.[3] Disease generally recurs at the primary tumor site, although concomitant neuraxis dissemination may also be seen. Systemic relapse is extremely rare.
At the time of relapse, a complete evaluation for the extent of recurrence is indicated for all patients.
Treatment options for recurrent childhood ependymoma include the following:
Surgery.
Sources: Surgery
Radiation therapy and/or chemotherapy.
Source: Childhood Ependymoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
The utility of further surgical intervention is individualized, based on the extent and location of the tumor. A study of 53 patients with recurrent ependymoma demonstrated an improved 5-year overall survival (OS) rate of 48.7% for patients who had gross-total or near-total resections at the time of surgery, compared with 5.3% for patients with less than gross-total or near-total resections.[4][Level of evidence B4]
Sources: 4 · Level of evidence B4
In some cases, surgically accessible lesions may be treated alternatively with radiation therapy.
Source: Childhood Ependymoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Patients with recurrent ependymomas should be considered for treatment with the following modalities:[5][Level of evidence C1]
Sources: 5 · Level of evidence C1
Focal retreatment with various radiation modalities, including stereotactic radiosurgery,[6-8][Level of evidence C1]; [9-11][Level of evidence C2]; [12] intensity-modulated photon therapy, and proton therapy.[13]; [14][Level of evidence C1]
Sources: stereotactic radiosurgery · 6 · 8 · Level of evidence C1 · 9 · 11 · Level of evidence C2 · 12 · proton therapy · 13 · 14 · Level of evidence C1
Craniospinal irradiation for both local and distant (spinal) recurrence could be considered.[15] A study of 101 reirradiated patients conducted at St. Jude Children's Research Hospital observed the following results:[13][Level of evidence C2]
Sources: 15 · 13 · Level of evidence C2
Craniospinal irradiation for both local and distant (spinal) recurrence could be considered.[15] A study of 101 reirradiated patients conducted at St. Jude Children's Research Hospital observed the following results:[13][Level of evidence C2]
The median duration of OS was 75.1 months, and the median freedom from progression was 27.3 months.
The 1-, 2-, and 5-year estimates of OS rates were 95.5%, 74.9%, and 57.3%, respectively.
Among the 46 patients who received focal reirradiation for local failure, 13 had local failures, and 11 had distant-only failures.
Among the ten patients who received craniospinal irradiation for local failure, six had local failures, and none had distant-only failures.
Patients with distant-only failure who were treated with craniospinal irradiation had improved OS compared with individuals with local failure who were treated with focal radiation therapy (hazard ratio [HR], 0.37; 95% confidence interval [CI], 0.16–0.87).
The 10-year cumulative incidence of greater than grade 3 radiation necrosis after repeat radiation therapy was 7.9%.
Gain of chromosome 1q was associated with poorer OS (HR, 3.5; 95% CI, 1.1–10.6) for patients with distant failure (but not local failure) after initial radiation therapy. Other variables associated with reduced OS and freedom from progression included male sex, anaplastic histology at recurrence, and a short interval from initial radiation therapy to recurrence.
In a study of 31 children with locally recurrent ependymomas, patients received local (conformal) radiation at recurrence. They received various fractionation schemes using radiation doses similar to those used at initial diagnosis.[16]
Sources: 16
In a study of 31 children with locally recurrent ependymomas, patients received local (conformal) radiation at recurrence. They received various fractionation schemes using radiation doses similar to those used at initial diagnosis.[16]
The median local recurrence-free survival was 31 months (range, 2–63 months), and the median OS was 34 months (range, 3–63 months).
Patients who underwent surgery first had significantly higher survival rates than did patients who received reirradiation only.
In contrast, a study of 53 patients with recurrent ependymomas treated with radiation therapy after surgery showed no advantage with the addition of radiation therapy after a gross-total or near-total resection.[4][Level of evidence B4]
Sources: 4 · Level of evidence B4
In contrast, a study of 53 patients with recurrent ependymomas treated with radiation therapy after surgery showed no advantage with the addition of radiation therapy after a gross-total or near-total resection.[4][Level of evidence B4]
There was an improvement in the 5-year OS rate (22% vs. 7%) for patients treated with radiation therapy who had less than gross-total or near-total resections.
Three, and even four, courses of radiation therapy for patients with recurrences can prolong survival with acceptable minimal toxicity.[13][Level of evidence C2]
Sources: 13 · Level of evidence C2
Active anticancer agents, including cyclophosphamide, cisplatin, carboplatin, lomustine, and etoposide, have been used in the recurrence setting. While older single-agent studies have demonstrated chemoresponsiveness with these agents, response is rarely durable.[17,18]
Regardless of treatment strategy, the prognosis for patients with recurrence is poor.[1] Entry into studies of novel therapeutic approaches should be considered.
Sources: 1
Source: Childhood Ependymoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025. Captured 2026-09-09.
Early-phase therapeutic trials may be available for selected patients. These trials may be available via the Children's Oncology Group (COG), the Pediatric Brain Tumor Consortium, or other entities. Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Sources: Children's Oncology Group (COG) · Pediatric Brain Tumor Consortium · NCI website · ClinicalTrials.gov website
Source: Childhood Ependymoma, National Cancer Institute.
Source updated: November 5, 2024. Captured 2026-09-09.
Source: Childhood Ependymoma, National Cancer Institute.
Source updated: November 5, 2024. Captured 2026-09-09.
A pediatric oncologist, a doctor who specializes in treating children with cancer, oversees treatment for childhood ependymoma. The pediatric oncologist works with other health care providers who are experts in treating children with brain tumors and also specialize in other areas of medicine. Other specialists may include:
Sources: brain tumors
pediatric neurosurgeon
Sources: neurosurgeon
neurologist
Sources: neurologist
pediatrician
Sources: pediatrician
radiation oncologist
Sources: radiation oncologist
pathologist
Sources: pathologist
pediatric nurse specialist
Sources: pediatric nurse specialist
social worker
Sources: social worker
medical oncologist
Sources: medical oncologist
endocrinologist
Sources: endocrinologist
rehabilitation specialist
Sources: rehabilitation specialist
psychologist
Sources: psychologist
child-life specialist
Sources: child-life specialist
fertility specialist
Sources: fertility specialist
There are different types of treatment for children and adolescents with ependymoma. You and your child's care team will work together to decide treatment. Many factors will be considered, such as where the cancer is located, your child's age and overall health, and the type and grade of the ependymoma.
Your child's treatment plan will include information about the cancer, the goals of treatment, treatment options, and the possible side effects. It will be helpful to talk with your child's care team before treatment begins about what to expect. For help every step of the way, see our booklet, Children with Cancer: A Guide for Parents.
The types of treatment your child might have include:
Source: Childhood Ependymoma, National Cancer Institute.
Source updated: November 5, 2024. Captured 2026-09-09.
Surgery to remove the tumor and some of the healthy tissue around it is usually the first treatment for childhood ependymoma. Surgery may be done to obtain a biopsy sample to confirm the diagnosis (see Tests to diagnose childhood ependymoma), relieve symptoms caused by the tumor pressing on the brain or spinal cord, and to remove as much of the tumor as possible.
An MRI is often done after the tumor is removed to find out whether any tumor remains. If tumor remains, a second surgery to remove as much of the remaining tumor as possible may be done.
Sources: MRI
Some children may be given chemotherapy or radiation therapy after surgery to kill any cancer cells that are left. Treatment given after surgery, to lower the risk that the cancer will come back, is called adjuvant therapy.
Sources: chemotherapy · radiation therapy · adjuvant therapy
Source: Childhood Ependymoma, National Cancer Institute.
Source updated: November 5, 2024. Captured 2026-09-09.
Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. Ependymoma is treated with external beam radiation therapy. This type of therapy uses a machine outside the body to send radiation toward the area of the body with cancer. Radiation therapy may be given alone or with other treatments, such as chemotherapy.
Certain ways of giving external beam radiation therapy can help keep radiation from damaging nearby healthy tissue. These include:
Conformal radiation therapy uses a computer to make a 3-dimensional (3-D) picture of the tumor and shapes the radiation beams to fit the tumor.
Sources: Conformal radiation therapy · 3-dimensional
Intensity-modulated radiation therapy (IMRT) is a type of 3-D radiation therapy that uses a computer to make pictures of the size and shape of the tumor. Thin beams of radiation of different intensities (strengths) are aimed at the tumor from many angles.
Proton-beam radiation therapy is a type of high-energy radiation therapy. A radiation therapy machine aims streams of protons (tiny, invisible, positively-charged particles) at the cancer cells to kill them.
Sources: Proton-beam radiation therapy · protons
Stereotactic radiosurgery uses a rigid head frame attached to the skull to keep the head still during the radiation treatment. A machine aims a single large dose of radiation directly at the tumor. This procedure does not involve surgery. It is also called stereotaxic radiosurgery, radiosurgery, and radiation surgery.
Sources: Stereotactic radiosurgery · skull
Younger children who receive radiation therapy to the brain have a higher risk of problems with growth and development than older children. 3-D conformal radiation therapy and proton-beam therapy are being studied in young children to see if it decreases the effects of radiation on growth and development.
Learn more about External Beam Radiation Therapy for Cancer and Radiation Therapy Side Effects.
Sources: External Beam Radiation Therapy for Cancer · Radiation Therapy Side Effects
Source: Childhood Ependymoma, National Cancer Institute.
Source updated: November 5, 2024. Captured 2026-09-09.
Chemotherapy (also called chemo) uses drugs to stop the growth of cancer cells. Chemotherapy either kills the cancer cells or stops them from dividing. Chemotherapy may be given alone or with other types of treatment, such as radiation therapy.
For ependymoma, chemotherapy is injected into a vein. When given this way, the drugs enter the bloodstream to reach cancer cells throughout the body. Chemotherapy that may be used alone or in combination includes:
Sources: injected
carboplatin
Sources: carboplatin
cisplatin
Sources: cisplatin
cyclophosphamide
Sources: cyclophosphamide
etoposide
Sources: etoposide
lomustine
Sources: lomustine
vincristine
Sources: vincristine
Other chemotherapy drugs not listed here may also be used.
Learn more at Chemotherapy to Treat Cancer.
Sources: Chemotherapy to Treat Cancer
Source: Childhood Ependymoma, National Cancer Institute.
Source updated: November 5, 2024. Captured 2026-09-09.
A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for people with cancer. Because cancer in children is rare, taking part in a clinical trial should be considered.
Find clinical trials for people with ependymoma at Ependymoma Clinical Trials, or use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. Some clinical trials are open only to patients who have not started treatment. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.
Sources: Ependymoma Clinical Trials · clinical trial search · ClinicalTrials.gov
Learn more at Clinical Trials Information for Patients and Caregivers.
Sources: Clinical Trials Information for Patients and Caregivers
Source: Childhood Ependymoma, National Cancer Institute.
Source updated: November 5, 2024. Captured 2026-09-09.
Treatment of newly diagnosed childhood ependymoma in the brain or brain stem includes surgery.
After surgery, the plan for further treatment depends on:
the ependymoma subtype
whether any cancer cells remain after surgery
whether the cancer has spread to other parts of the brain or spinal cord
your child's age
When the tumor is completely removed and cancer cells have not spread, treatment may include radiation therapy.
When part of the tumor remains after surgery, but cancer cells have not spread, treatment may include:
a second surgery to remove as much of the remaining tumor as possible
radiation therapy
chemotherapy before radiation therapy
When cancer cells have spread within the brain and spinal cord, treatment may include:
radiation therapy to the brain and spinal cord
chemotherapy
Treatment for children younger than 1 year of age may include:
chemotherapy
a clinical trial of 3-dimensional (3-D) conformal radiation therapy or proton-beam radiation therapy
Sources: 3-dimensional (3-D) conformal radiation therapy · proton-beam radiation therapy
Radiation therapy is not given to children until they are older than 1 year.
To learn more about these treatments, see Types of treatment for childhood ependymoma.
Source: Childhood Ependymoma, National Cancer Institute.
Source updated: November 5, 2024. Captured 2026-09-09.
Treatment of newly diagnosed childhood myxopapillary spinal ependymoma (grade 2) is surgery. Sometimes radiation therapy is given after surgery.
Treatment of newly diagnosed childhood nonmyxopapillary spinal ependymoma is surgery. Sometimes radiation therapy is given after surgery for children with grade 2 or grade 3 tumors.
To learn more about these treatments, see Types of treatment for childhood ependymoma.
Source: Childhood Ependymoma, National Cancer Institute.
Source updated: November 5, 2024. Captured 2026-09-09.
Treatment of recurrent childhood ependymoma may include:
Sources: recurrent
surgery
external beam radiation therapy
chemotherapy
To learn more about these treatments, see Types of treatment for childhood ependymoma.
Source: Childhood Ependymoma, National Cancer Institute.
Source updated: November 5, 2024. Captured 2026-09-09.
Cancer treatments can cause side effects. Which side effects your child might have depends on the type of treatment they receive, the dose, and how their body reacts. Talk with your child’s treatment team about which side effects to look for and ways to manage them.
To learn more about side effects that begin during treatment for cancer, visit Side Effects.
Sources: side effects · Side Effects
Problems from cancer treatment that begin 6 months or later after treatment and continue for months or years are called late effects. Late effects of treatment for childhood ependymoma may include:
physical problems, including problems with:
physical problems, including problems with:
tooth development
hearing function
bone and muscle growth and development
thyroid function
Sources: thyroid
blood clots and broken vessels in the brain, leading to stroke
Sources: stroke
changes in mood, feelings, thinking, learning, or memory
second cancers (new types of cancer), such as thyroid cancer or brain cancer
Sources: thyroid cancer
Some late effects may be treated or controlled. It is important to talk with your child's doctors about the effects cancer treatment can have on your child. Learn more about Late Effects of Treatment for Childhood Cancer.
Brain Tumor, Central Nervous System Tumor
ClinicalTrials.gov recordAnaplastic Ependymoma, Brain Ependymoma, Cellular Ependymoma, Clear Cell Ependymoma, Ependymoma, Papillary Ependymoma
ClinicalTrials.gov recordChildhood Cerebellar Anaplastic Astrocytoma, Childhood Cerebral Anaplastic Astrocytoma, Childhood Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Mixed...
ClinicalTrials.gov recordEpendymoma in children and adolescents
Treatment of Recurrent Childhood Ependymoma